BHC · Bausch Health Companies Inc

Current Thesis

Bausch Health’s debt-reduction and Bausch + Lomb separation story has lost its published price support: the 2026-09-11 close of $5.86 breached the $5.90 weekly threshold specified on 2026-08-30. The fundamental case still rests on the raised guidance announced on 2026-07-29, but the post-earnings price thesis has already been invalidated.

The life-cycle assessment is an inference: the narrative is dead for the previously defined post-earnings leg because the week ended 2026-09-11 closed below its published condition. This finding concerns that price thesis; it does not establish that the company’s debt-reduction programme has failed.

Since the previous note, the company announced Australian availability of Fraxel FTX on 2026-09-01 and both YUN market expansion and Alberta reimbursement for SILIQ on 2026-09-08. These are commercial developments; the release index contains no subsequent earnings or guidance announcement through the 2026-09-13 review. Bausch Health releases

Bullish and bearish views on Bausch Health Companies Inc

The model's bull view on Bausch Health Companies Inc (BHC), in brief: Operating growth supports the premise. On 2026-07-29, Bausch Health reported second-quarter consolidated revenue of $2,852 million, up 13% year over year, and adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) of $1,075 million, up 28%. These… The bear view: The published threshold has failed. The adjusted market close of $5.86 on Friday, 2026-09-11 was below the $5.90 weekly thesis-break level published on 2026-08-30. Retaining the original threshold records the failure without moving the condition after the event. Debt competes… Both cases follow in full.

Bull Case

• Operating growth supports the premise. On 2026-07-29, Bausch Health reported second-quarter consolidated revenue of $2,852 million, up 13% year over year, and adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) of $1,075 million, up 28%. These results provide operating evidence for the turnaround case. Second-quarter results
• Guidance provides a measurable test. The 2026-07-29 presentation set full-year adjusted EBITDA excluding Bausch + Lomb at $3.025–3.1 billion. A subsequent reduction would contradict the earnings premise behind the July repricing.
• Product access has expanded. The 2026-09-08 announcement added SILIQ to Alberta’s public drug plan for eligible plaque psoriasis patients. The release index supplies no incremental revenue figure, so the financial contribution cannot be quantified from that evidence. Company announcement index

Bear Case

• The published threshold has failed. The adjusted market close of $5.86 on Friday, 2026-09-11 was below the $5.90 weekly thesis-break level published on 2026-08-30. Retaining the original threshold records the failure without moving the condition after the event.
• Debt competes with operating progress. The supplied Form 10-Q evidence for 2026-06-30 reports long-term debt principal of $20,239 million and first-half interest expense of $798 million. Those filed amounts explain why revenue growth alone does not establish successful deleveraging.
• Salix carries impairment evidence. The Form 10-Q for 2026-06-30 recorded a $1,426 million Salix goodwill impairment following failed Phase 3 trials. The same filing assigned the $808 million Xifaxan intangible an estimated remaining useful life of 18 months; neither figure establishes a guaranteed commercial exclusivity period.

Setup & Price Structure

Measured on 2026-09-11, BHC closed at $5.86, stood 25.8% below its $7.90 trailing-year high and retained a three-month price increase of 15.8%. Its 14-period relative strength index (RSI) was 36.9. The positive three-month change therefore coexists with a breach of the previously published weekly condition.

The dated evidence does not establish current crowding. No current moving-average level, short-interest figure, fund-flow series or verified insider-sale series is available in this record. The price and RSI observations cannot identify which participants account for the weakness.

Catalyst Calendar (next 30 days)

• 2026-09-13 through 2026-10-13: No company-confirmed event in this window was identified in the investor calendar reviewed on 2026-09-13; its upcoming-events section was empty. This is a calendar limitation, not a prediction that no announcement will occur. Company events calendar
• ~2026-10-29, estimated: Third-quarter results remain the next identified test of the 2026-07-29 guidance. TipRanks carries this date but inconsistently describes it as both confirmed and estimated; absent a company announcement, it remains an estimate outside the next-month window. Earnings calendar

What Would Change Our Mind

The loss of the published price support has already settled the original condition: a weekly close below $5.90 occurred with the 2026-09-11 close of $5.86. A subsequent recovery cannot erase that recorded invalidation.

A weekly close back above the published $5.90 threshold, accompanied by the next results retaining the 2026-07-29 adjusted EBITDA guidance of $3.025–3.1 billion excluding Bausch + Lomb, would provide grounds to reassess a recovery case. A renewed weekly close below $5.90 or a reduction in that guidance would defeat that reassessment.

Correlation Notes

This remains a company-specific debt-reduction and separation case. The 2026-06-30 filing evidence places Bausch Health’s ownership of Bausch + Lomb at approximately 87%, while the 2026-07-29 presentation reports second-quarter subsidiary revenue of $1,394 million. That ownership supplies an economic link to BLCO; it does not establish a measured share-price correlation.

No paired return sample is supplied as of 2026-09-11. The evidence therefore supports neither a numerical correlation claim nor an inference that a broader biotechnology advance would repair BHC’s broken price structure.